Market Overview

Markets are returning from the Fourth of July break with a risk-on tone. Tech futures are rallying led by memory/semiconductor names (Micron, SanDisk bouncing), while Goldman Sachs projects a 22% YoY earnings surge for Q2 driven by AI and energy. The Dow is lagging as chip and growth names absorb the bid, creating a rotation dynamic favoring Nasdaq over blue chips.

Claude’s Call

UP — S&P 500 trends higher today as chip stocks rebound, biotech/healthcare momentum continues from June’s leadership, and post-holiday positioning favors risk assets with Fed minutes due later this week providing no immediate headwind.

Top Movers

PLBL (+6.21%) — $10.81 → No clear target without technicals Thesis: Up 38% on the week with no identifiable news catalyst — this screams low-float squeeze or speculative momentum play. RSI at 39.9 is oddly low given the weekly surge, suggesting the move is fresh and hasn’t fully registered on oscillators yet, but the absence of any fundamental driver makes this a pure technical/flow trade. Levels: No technical data available. Treat prior week’s low (~$7.80 implied from +38% weekly) as support. Fade if no news emerges.

KB (+4.13%) — $113.59 → $120-125 range (+6-10% upside) Thesis: Korean financials are catching a bid from multiple tailwinds — KB reported strong Q1 with KRW 1.89T net income, 15% profit growth in FY25 driven by non-interest income, and South Korean equities are broadly rallying on household investment inflows. This is a legitimate fundamental story (cheap valuation, rising shareholder returns) riding a secular bid for Korean banks. Levels: Support near $98-100 (pre-rally base). Resistance at 52-week highs likely in the $120s given the 15.5% weekly move.

CMBT (+3.98%) — $15.17 → $17-18 (+12-19% upside) Thesis: CMB.Tech’s net income exploded 738% in Q1 driven by the Strait of Hormuz shipping disruption — this is a geopolitical premium play on freight rates. With US-Iran talks stalled and $200M in approved shareholder distributions, this is real cash generation, not hype. The risk is a sudden peace deal collapsing freight rates overnight. Levels: Support near $14 (prior breakout level). New 52-week highs suggest blue sky above.

QLYS (+3.52%) — $155.28 → $170-175 (+10-13% upside) Thesis: JPMorgan upgraded to Neutral (from Underweight likely) citing stronger demand for vulnerability management in the AI era. Up 26% on the week from oversold levels (RSI was 39.2). Cybersecurity is a secular winner and Qualys has been punished for being “boring” — this re-rating has room if estimates start moving up. However, some analysts flag it as overvalued on DCF. Levels: Support at $125-130 (pre-rally base). Resistance at $170-175 (prior range from 6 months ago).

RIVN (+2.88%) — $19.11 → $22-23 (+15-20% upside) Thesis: California’s new EV incentives explicitly exclude Tesla and benefit Rivian/Lucid, the company just raised its 2026 delivery outlook, and the stock is bouncing from deeply oversold levels (RSI 19.3). Up 22% on the week but still trading at a fraction of its IPO price. The fundamental story is improving — gross margin inflection is the key catalyst ahead. Levels: Support at $15.50-16 (recent lows implied by RSI). Resistance at $22-24 (prior consolidation zone).

RMD (+3.46%) — $216.29 → $250-270 (+16-25% upside) Thesis: Goldman Sachs added ResMed to its APAC Conviction List, Zacks upgraded to Buy, and analysts see 28% upside. The stock is down 23% over the past year despite recurring revenue from sleep apnea devices/software — classic value setup. Removed from Russell Growth indices creates forced selling that’s now exhausted, setting up a mean reversion. Levels: Support at $200-205 (recent lows). Resistance at $250+ (pre-decline levels).

BETA (+2.94%) — $18.53 → $22-24 (+19-30% upside) Thesis: Electric aviation play with a $3.9B aircraft backlog, new Palantir AI partnership for SurfOS, and Hawaii electric flight demo. RSI at 9.3 is absurdly oversold — this is bouncing from max pessimism. Pre-revenue stage company burning $97M/quarter adjusted EBITDA, so this is high-risk speculation, but the backlog provides some valuation floor. Levels: Support at $16 (recent low). Resistance at $22-25 (prior trading range).

Headlines to Watch

  • Goldman projects 22% Q2 earnings surge driven by AI — Sets a high bar for earnings season starting next week; beats need to be substantial to move stocks.
  • California EV incentives exclude Tesla, benefit Rivian/Lucid — Direct policy tailwind for RIVN with real demand implications in the largest US EV market.
  • Chip stocks rebounding post-holiday (MU, SNDK) — Memory cycle inflection thesis getting fresh legs; watch for follow-through above Friday’s highs.
  • Fed Minutes due this week — Market needs confirmation of dovish tilt; any hawkish surprise could derail the risk-on trade.
  • Biotech, China, insurance led June ETF gains — Sector leadership breadth is healthy; not just mega-cap tech carrying the market.
  • US-Iran talks stalled — Keeps shipping/energy premiums elevated; directly benefits CMBT and energy names.
  • Samsung denies Open USD stablecoin partnership — Korean tech/financial names (SHG, KB) may see volatility from crypto-adjacent headline risk.

Claude’s Top Picks

RMD (+3.46% today, +7.99% week) — $216.29 → $260 (+20.2% upside) Valuation: Down 23% from highs with Goldman conviction buy and Zacks upgrade — trading cheap vs. its own history on recurring sleep apnea revenue. Upside: Forced selling from Russell Growth index removal is exhausted, creating a technical floor for institutional re-accumulation. Risk: If GLP-1 obesity drugs continue to reduce sleep apnea prevalence, the secular growth narrative erodes.

RIVN (+2.88% today, +22.26% week) — $19.11 → $23 (+20.4% upside) Valuation: Still trading at ~2x forward EV/Revenue which is expensive for an unprofitable EV maker, but cheap vs. its own history and improving fundamentals. Upside: Raised 2026 guidance + California incentive tailwind + RSI of 19 screaming oversold bounce with room to $22-24. Risk: Cash burn remains massive; any capital raise or delivery miss would crush the rally.

KB (+4.13% today, +15.52% week) — $113.59 → $125 (+10.1% upside) Valuation: Korean banks trade at ~5-6x earnings with 15% profit growth — dirt cheap vs. US bank peers at 10-12x. Upside: Shareholder return programs accelerating, non-interest income diversifying revenue, Korean equity market inflows providing macro tailwind. Risk: Won/dollar exchange rate volatility and Middle East geopolitical overhang on Korean export economy.

CMBT (+3.98% today, +7.59% week) — $15.17 → $18 (+18.7% upside) Valuation: Trading at low single-digit P/E given 738% profit growth — absurdly cheap if freight rates sustain. Upside: Hormuz disruption isn’t resolving anytime soon with US-Iran talks stalled; $200M shareholder distribution approved. Risk: Binary geopolitical exposure — a peace deal or shipping route reopening would crater earnings overnight.

BETA (+2.94% today, +10.96% week) — $18.53 → $22 (+18.7% upside) Valuation: $3.9B backlog on a ~$3-4B enterprise value is reasonable for an aerospace development-stage company. Upside: RSI at 9.3 is the most oversold name in the entire list — pure mean reversion setup with Palantir catalyst. Risk: Pre-revenue cash burn of ~$100M/quarter; insider selling (president sold 45K shares); certification timeline delays could extend losses.

Avoid

PLBL (+6.21% today, +38.1% week) — No identifiable catalyst, no news, extreme weekly move with vol ratio at just 1.0x. This is a mystery mover that could reverse as fast as it rallied. Chasing a 38% weekly gain without understanding why is how accounts blow up.

LMRI (+4.59% today, RSI 72.8) — Already the most overbought name in the top 20 list. Good fundamental story (18.6% EBITDA growth, PET/MRI modality expansion) but the easy money has been made; RSI above 70 signals fading momentum ahead.

DRTS (+3.36% today, +27.3% week) — Alpha Tau just got added to Zacks Strong Sell list on July 2nd despite the rally. The Tolmar prostate cancer deal is real but clinical-stage biotech with no revenue trading on hope after a 27% weekly run is a classic retail trap.

WSB Sentiment Check

MU — WSB says: BULLISH (80% bullish) Claude says: AGREE — Memory cycle inflection is real, Micron is rebounding post-holiday, and AI-driven HBM demand provides a secular floor. The trade is crowded but directionally correct; buy pullbacks, don’t chase gap-ups.

MSFT — WSB says: BULLISH (80% bullish) Claude says: AGREE — Microsoft’s AI monetization through Copilot/Azure is the cleanest large-cap AI play. At ~30x forward earnings with 15%+ growth, valuation is full but not egregious. WSB is right to be long but this isn’t a momentum trade — it’s a compounder.

WEN — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Wendy’s is a low-growth QSR name trading at a premium to peers; 87 mentions with 917 upvotes smells like a meme pump on a fundamentally mediocre business. Consumer discretionary faces headwinds from inflation-weary consumers. This is likely a short-squeeze attempt that fizzles.

NVDA — WSB says: BULLISH (80% bullish) Claude says: AGREE — NVDA remains the AI infrastructure kingpin. At ~35x forward earnings growing 50%+, the PEG ratio is under 1x — it’s genuinely cheap for its growth rate. The consensus is right here; don’t fight the trend.

SNDK — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY — SanDisk benefits from the same memory cycle thesis as MU, but as a recent spin-off it has less institutional coverage and more execution risk. The thesis is sound but the risk/reward is better in MU directly. Follow-the-leader trades tend to underperform the leader.